课题基金 / 基金详情

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions
使用混合数字孪生解决方案对肥厚型心肌病患者进行分层、管理和指导
批准号:
10109598
负责人:
金额:
$100.63万
依托单位:
依托单位国家:
英国
项目类别:
EU-Funded
财政年份:
2024
资助国家:
英国
项目状态:
未结题
起止时间:
2024 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickeningof cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death amongyoung athletes. Comorbidities due to gene mutations include altered vascular control, and, caused by HCM, ischemia, stroke, dementia,or psychological and social difficulties. Multiple causal mutations and variations in cellular processes lead to highly diverse phenotypesand disease progression. However, HCM is still diagnosed as one single disease, leading to suboptimal care. SMASH-HCM will developa digital-twin platform to dramatically improve HCM stratification and disease management, both for clinicians and patients. Multileveland multiorgan dynamic biophysical and data-driven models are integrated in a three-level deep phenotyping approach designed forfast uptake into the clinical workflow. SMASH-HCM unites 8 research partners, 3 hospitals, 3 SMEs, and a global health-technologycorporation in collaboration with patients to advance the state of the art in human digital-twins: including in-vitro tools, in-silico frommolecular to systemic level models, structured and unstructured data analysis, explainable artificial intelligence - all integrated intoa decision support solution for both healthcare professionals and patients. SMASH-HCM delivers new insights into HCM, improvedpatient care and guidance, validated preclinical tools, and above all, a first HCM stratification and management strategy, validated in apilot clinical trial, and tested with end users. Thus providing a cost efficient and effective solution for this complex disease. SMASHHCM develops a strategy towards fast regulatory approval. In reaching its goals, SMASH-HCM serves as a basis for future digital-twinplatforms for other cardiac diseases integrating models and data from various scales and sources.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
海外基金